TM6SF2 and hepatocellular carcinoma: There are also emerging genetic and proteomic markers such as: (i) PNPLA3 and TM6SF2 polymorphisms: genetic variants associated with increased risk of fibrosis and HCC and (ii) proteomic and metabolomic approaches: novel biomarkers are being explored for early detection and personalised risk prediction.